VALN

Valneva
VALN
Market cap $470M

5.80 USD

-0.04

0.68%

At close Oct 9, 4:00 PM EDT

1 day

-0.68%

5 days

2.65%

1 month

-16.18%

3 months

-20.00%

6 months

-27.86%

Year to date

-43.36%

1 year

-48.85%

5 years

-79.54%

About: Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The company generates the majority of its revenue from product sales.

Employees: 676

0

Funds holding %

of 6,740 funds

0

Analysts bullish %

of 5 analysts

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

100% more repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 1

30% more capital invested

Capital invested by funds: $3.64M [Q1] → $4.73M (+$1.09M) [Q2]

0.14% more ownership

Funds ownership: 0.33% [Q1] → 0.47% (+0.14%) [Q2]

0% more funds holding

Funds holding: 11 [Q1] → 11 (+0) [Q2]

0% more first-time investments, than exits

New positions opened: 2 | Existing positions closed: 2

See Fund Rankings

Research analyst outlook

5 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$23

297%

upside

Avg. target

$25

338%

upside

High target

$26

348%

upside

5 analyst ratings

5 positive

100%

0 neutral

0%

0 negative

0%

HC Wainwright & Co. Edward White 31% 1-year accuracy 11 / 36 met price target	297%upside $23	Buy Maintained	25 Sept 2024
HC Wainwright & Co. Edward White 31% 1-year accuracy 11 / 36 met price target	348%upside $26	Buy Reiterated	3 Sept 2024
HC Wainwright & Co. Edward White 31% 1-year accuracy 11 / 36 met price target	348%upside $26	Buy Reiterated	14 Aug 2024
HC Wainwright & Co. Edward White 31% 1-year accuracy 11 / 36 met price target	348%upside $26	Buy Reiterated	2 Aug 2024
HC Wainwright & Co. Edward White 31% 1-year accuracy 11 / 36 met price target	348%upside $26	Buy Reiterated	22 Jul 2024

See Analyst Rankings

Financial journalist opinion

Based on 4 articles about VALN published over the past 30 days

Valneva to Host Investor Day in New York on Thursday, October 10, 2024 at 10:00 AM ET

Saint Herblain (France), October 3, 2024 –Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that it will host an investor day at the Lotte New York Palace Hotel in New York, NY on Thursday, October 10, 2024 at 10:00 AM ET (4:00 pm CET). The meeting will be conducted in a hybrid way – in person and webcast. To register, click here.

Valneva to Host Investor Day in New York on Thursday, October 10, 2024 at 10:00 AM ET

Valneva Submits Label Extension Applications for its Chikungunya Vaccine, IXCHIQ®, to EMA and Health Canada

To potentially include adolescents and antibody persistence up to two years Saint Herblain (France), September 18, 2024 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that it has submitted label extension applications to the European Medicines Agency (EMA) and Health Canada to potentially expand the use of its chikungunya vaccine, IXCHIQ®, to adolescents aged 12 to 17 years in Europe and Canada. The Canadian label extension application also includes two-year antibody persistence data, which is a key differentiator for IXCHIQ® that was already included in the initial EMA filing.

Valneva Submits Label Extension Applications for its Chikungunya Vaccine, IXCHIQ®, to EMA and Health Canada

Valneva Announces the Success of its Private Placement Raising approximately €60 Million

Saint-Herblain (France), September 13, 2024 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) (“Valneva” or the “Company”), a specialty vaccine company, today announces the successful pricing of its Private Placement (as defined below) for a final amount of €61,180,000.

Valneva Announces the Success of its Private Placement Raising approximately €60 Million

Valneva Announces the Launch of a Private Placement of Ordinary Shares for Approximately 60 Million Euros

Saint-Herblain (France), September 12, 2024 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) (“Valneva” or the “Company”), a specialty vaccine company, today announces its intention to issue, subject to market conditions, approximately 22.6 million new ordinary shares (the “Offer Shares”) at a price of €2.66 per Offer Share to certain categories of investors via a private placement through an accelerated bookbuilding process starting immediately.

Valneva Announces the Launch of a Private Placement of Ordinary Shares for Approximately 60 Million Euros

Zacks Investment Research

Favorable VLA15 Phase 2 Study Results Might Boost VALN Stock

Valneva and Pfizer report positive immunogenicity and safety data from their Phase 2 study of the VLA15 vaccine. Phase 3 trials for VLA15 are in progress.

Favorable VLA15 Phase 2 Study Results Might Boost VALN Stock

Pfizer and Valneva report positive results in mid-stage trial of Lyme disease vaccine

The Phase 2 trial was evaluating the vaccine called VLA15 following a second booster dose given one year after the first one.

Pfizer and Valneva report positive results in mid-stage trial of Lyme disease vaccine

Valneva and Pfizer Report Further Positive Phase 2 Booster Results for Lyme Disease Vaccine Candidate

Saint-Herblain (France) and New York, NY, September 3, 2024 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) and Pfizer Inc. (NYSE: PFE) announced today positive immunogenicity and safety data from their VLA15-221 Phase 2 study following a second booster vaccination of their Lyme disease vaccine candidate, VLA15, given one year after receiving the first booster dose. The immune response and safety profile of VLA15 one month after receiving the second booster dose were similar to those reported after receiving the first booster dose, showing compatibility with the anticipated benefit of a booster vaccination prior to each Lyme season. There are currently no approved human vaccines for Lyme disease, and VLA15 is the Lyme disease vaccine candidate which has advanced the furthest along the clinical development timeline, with two Phase 3 trials in progress. The Centers for Disease Control and Prevention (CDC) has estimated that approximately 476,000 people in the U.S. are diagnosed and treated for Lyme disease each year and 129,000 cases are reported annually in Europe.1 , 2

Valneva and Pfizer Report Further Positive Phase 2 Booster Results for Lyme Disease Vaccine Candidate

Zacks Investment Research

Wall Street Analysts Predict a 150.41% Upside in Valneva (VALN): Here's What You Should Know

The consensus price target hints at a 150.4% upside potential for Valneva (VALN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Wall Street Analysts Predict a 150.41% Upside in Valneva (VALN): Here's What You Should Know

Zacks Investment Research

How Much Upside is Left in Valneva (VALN)? Wall Street Analysts Think 135.3%

The consensus price target hints at a 135.3% upside potential for Valneva (VALN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

How Much Upside is Left in Valneva (VALN)? Wall Street Analysts Think 135.3%

Valneva Reports Half Year 2024 Financial Results and Provides Corporate Updates

First-Half Sales Performance in Line with Full-Year 2024 Guidance Total revenues of €70.8 million, including product sales of €68.3 million, in line with anticipated supply and sales phasing Net Profit of €34.0 million, including proceeds from PRV sale Operating profit of €46.7 million compared to an operating loss of €35.0 million in the first half of 2023 Cash position of €131.4 million Substantially lower cash burn expected in the second half of 2024 as Valneva completed its cost contributions to the agreed R&D budget for its partnered Lyme disease program in the second quarter Significantly extended cash runway with update of debt financing agreement1 Full-year 2024 Financial Guidance Confirmed Expected total revenues between €170 million and €190 million, including €160 million to €180 million of product sales Expected R&D investments between €60 million and €75 million Expected Other income between €100 million and €110 million, including €95 million from the PRV sale Strategic Pipeline Expansion, Strong Clinical and Regulatory Execution Exclusive worldwide license for S4V Shigella vaccine candidate, adding an attractive Phase 2 clinical asset to Valneva's R&D pipeline without impacting full-year or mid-term financial guidance2 Additional marketing authorizations for single-shot IXCHIQ® granted in Europe and Canada ahead of initial guidance; Ongoing regulatory reviews in the UK and Brazil; Recommended by ACIP and adopted by U.S. CDC3 New CEPI grant4 of $41.3 million contributes significantly to Phase 4 costs and other studies supporting broader access to the world's first chikungunya vaccine Reported positive six-month data for Phase 3 adolescent study of IXCHIQ® 5; expects to submit label extensions for 12 to 17 years old in the U.S., Europe and Canada in the second half of 2024 IXCHIQ® two-year antibody persistence data published in the Lancet Infectious Diseases IXCHIQ® pediatric Phase 2 study fully enrolled Completed primary vaccinations (three doses) of VALOR Lyme disease Phase 3 trial participants6 Initiated Phase 1 clinical trial for second-generation Zika vaccine candidate7 Financial Information (Unaudited results, consolidated per IFRS) € in million 6 months ended June 30, 2024 2023 Total revenues 70.8 73.7 Product sales 68.3 69.7 Net profit / loss 34.0 (35.0) Adjusted EBITDA8 56.2 (28.3) Cash 131.4 204.4 Saint-Herblain (France), August 13, 2024 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today reported its consolidated financial results for the first half of the year, ended June 30, 2024. The half year financial report, including the condensed consolidated interim financial report and the half year management report, is available on the Company's website (Financial Reports – Valneva).

Valneva Reports Half Year 2024 Financial Results and Provides Corporate Updates

See News Rankings

Charts implemented using Lightweight Charts™